TOMTOM
25.10.2016 07:32:28 CEST | Business Wire | Press release
Marking a significant milestone for its Consumer business, TomTom (TOM2 ) today announces a major advertising campaign supporting TomTom Sports: Get Going . The campaign reinforces TomTom’s commitment to continue to launch Sports Wearables that inspire people to move. Created in partnership with Amsterdam-based agency Pool Worldwide, the campaign spans global markets with television, cinema, print, digital and out of home ad placements.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161024006174/en/
“Since 2011 we’ve set out to create Sports products that inspire people to move by taking away barriers and celebrating achievements. We were the first to integrate an optical Heart-Rate monitor into a GPS running watch and by integrating a music player we empowered people to leave increasingly larger and heavier phones at home. We have recently launched the world’s first fitness tracker that combines body composition analysis with steps, sleep and all day heart-rate tracking, right from the wrist – answering the age-old question ‘is what I’m doing, doing anything for me’. Today we’re incredibly proud to launch the Get Going campaign to further strengthen the TomTom Sports brand.” said Corinne Vigreux, Co-Founder and Managing Director, TomTom Consumer.
Patrick Stal, VP of Marketing for TomTom Sports adds: “This campaign marks a milestone for our brand. It showcases a TomTom Sports brand that caters to the needs of audiences ranging from those that are taking their first step down the road, to those that are stepping over the starting line of their first marathon. We are claiming a unique space in the world of sports. TomTom Sports is not here to shout at you to beat the impossible, be unstoppable, go harder, tougher, longer, deeper, rougher or sweatier. Let other sports brands do that. We want to help people where they need it most. Right at the beginning, where excuses often beat conviction. We want to be the brand that inspires people to Get Going and take that first step, no matter how big or small their effort might be, time and time again.”
For more information, visit http://getgoing.tomtom.com/en_gb .
Watch the hero ad here .
Credits:
End responsible at TomTom: Patrick Stal, Kelly McConville
Concept: Pool Worldwide
Creative Strategy: Pool Worldwide
Account: Pool Worldwide
RTV Producer: Sio van Bochove
Production Company: Pool Worldwide
Director: Paul Meijer
Producer: Sio van Bochove
Editor: Robert van Ees
Post production: The Ambassadors
Sound studio: The Ambassadors
-ENDS-
About TomTom Sports
TomTom Sports is on a mission to help you get going.
Since 2011, we’ve developed Sports and Fitness products that make it easier to get moving.
We were the first to add an optical heart-rate monitor to a GPS Sports Watch with TomTom Cardio , and by integrating a music player into our Sports Watches have enabled you to leave your smartphone at home. We’ve always been focused on innovating to make it easier to get going.
We also recently launched TomTom Touch , the first fitness tracker that combines body composition analysis with steps, sleep and all day heart-rate tracking, right from the wrist, technology usually reserved for elite athletes.
Find the full TomTom Sports product lineup here .
About TomTom
At TomTom (TOM2) our mission is to make technology so easy to use, that everyone can achieve more.
We created easy to use navigation devices, helping millions of people to get where they want to be. Today, we continue to simplify the complex, making technology more accessible for everyone.
We serve four different markets: Consumer, Telematics, Automotive and Licensing.
We make easy to use navigation devices, sport watches and action cameras for consumers. We enable businesses with vehicles to more easily manage and improve fleet efficiency whilst increasing overall business performance with our Telematics solutions. We also offer a world leading real-time map platform that is powering innovative location based services and helping to make automated driving a reality for the automotive industry.
Founded in 1991 and headquartered in Amsterdam, we have over 4,600 employees and sell our products worldwide.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006174/en/
Contact:
TomTom
Media
Lindsay Mandeville
+31 6 11
334292
lindsay.mandeville@tomtom.com
or
Investor
Relations
Bisera Grubesic
+31 20 75 75 194
ir@tomtom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom